Figure 3.
Estimates of the probability of DFS, NRM, and relapse among patients with intermediate-risk cytogenetics who received a therapeutic dose of 131I-BC8 antibody, followed by BU/CY.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.